Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer

Marialuisa Sponziello, Silvia Benvenuti, Alessandra Gentile, Valeria Pecce, Francesca Rosignolo, Anna Rita Virzì, Melissa Milan, Paolo M. Comoglio, Eric Londin, Paolo Fortina, Agnese Barnabei, Marialuisa Appetecchia, Ferdinando Marandino, Diego Russo, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Whole exome sequencing (WES) was used to investigate two Italian siblings with wild-type RET genotype, who developed medullary thyroid cancers (MTCs) and, later, primary prostate and breast cancers, respectively. The proband's MTC harbored a p.Met918Thr RET mutation; his sister's MTC was RET/RAS wild-type. Both siblings had a germline mutation (p.Arg417Gln) in the extracellular Sema domain of the proto-oncogene MET. Experiments involving ectopic expression of MET p.Arg417Gln in MET-negative T47D breast cancer cells documented the mutant receptor's functionality and its ability to enhance cell migration and invasion. Our findings highlight a possible link between MET germline mutations and MTCs and suggest that MET p. Arg417Gln may promote an invasive malignant phenotype. The possibility that MTC can be driven/co-driven by a MET mutation has potential management implications, since the tyrosine-kinase inhibitor cabozantinib—approved for treating advanced MTCs—is a specific MET inhibitor.

Original languageEnglish
Pages (from-to)371-377
Number of pages7
JournalHuman Mutation
Volume39
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Exome
Germ-Line Mutation
Breast Neoplasms
Mutation
Proto-Oncogenes
Protein-Tyrosine Kinases
Cell Movement
Prostatic Neoplasms
Genotype
Medullary Thyroid cancer
Phenotype

Keywords

  • familial medullary thyroid cancer
  • medullary thyroid cancer
  • MET proto-oncogene
  • RET proto-oncogene
  • whole exome sequencing

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Sponziello, M., Benvenuti, S., Gentile, A., Pecce, V., Rosignolo, F., Virzì, A. R., ... Verrienti, A. (2018). Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. Human Mutation, 39(3), 371-377. https://doi.org/10.1002/humu.23378

Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. / Sponziello, Marialuisa; Benvenuti, Silvia; Gentile, Alessandra; Pecce, Valeria; Rosignolo, Francesca; Virzì, Anna Rita; Milan, Melissa; Comoglio, Paolo M.; Londin, Eric; Fortina, Paolo; Barnabei, Agnese; Appetecchia, Marialuisa; Marandino, Ferdinando; Russo, Diego; Filetti, Sebastiano; Durante, Cosimo; Verrienti, Antonella.

In: Human Mutation, Vol. 39, No. 3, 01.03.2018, p. 371-377.

Research output: Contribution to journalArticle

Sponziello, M, Benvenuti, S, Gentile, A, Pecce, V, Rosignolo, F, Virzì, AR, Milan, M, Comoglio, PM, Londin, E, Fortina, P, Barnabei, A, Appetecchia, M, Marandino, F, Russo, D, Filetti, S, Durante, C & Verrienti, A 2018, 'Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer', Human Mutation, vol. 39, no. 3, pp. 371-377. https://doi.org/10.1002/humu.23378
Sponziello, Marialuisa ; Benvenuti, Silvia ; Gentile, Alessandra ; Pecce, Valeria ; Rosignolo, Francesca ; Virzì, Anna Rita ; Milan, Melissa ; Comoglio, Paolo M. ; Londin, Eric ; Fortina, Paolo ; Barnabei, Agnese ; Appetecchia, Marialuisa ; Marandino, Ferdinando ; Russo, Diego ; Filetti, Sebastiano ; Durante, Cosimo ; Verrienti, Antonella. / Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. In: Human Mutation. 2018 ; Vol. 39, No. 3. pp. 371-377.
@article{5f1c20e7b56e4b00b8cc644acc4941cf,
title = "Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer",
abstract = "Whole exome sequencing (WES) was used to investigate two Italian siblings with wild-type RET genotype, who developed medullary thyroid cancers (MTCs) and, later, primary prostate and breast cancers, respectively. The proband's MTC harbored a p.Met918Thr RET mutation; his sister's MTC was RET/RAS wild-type. Both siblings had a germline mutation (p.Arg417Gln) in the extracellular Sema domain of the proto-oncogene MET. Experiments involving ectopic expression of MET p.Arg417Gln in MET-negative T47D breast cancer cells documented the mutant receptor's functionality and its ability to enhance cell migration and invasion. Our findings highlight a possible link between MET germline mutations and MTCs and suggest that MET p. Arg417Gln may promote an invasive malignant phenotype. The possibility that MTC can be driven/co-driven by a MET mutation has potential management implications, since the tyrosine-kinase inhibitor cabozantinib—approved for treating advanced MTCs—is a specific MET inhibitor.",
keywords = "familial medullary thyroid cancer, medullary thyroid cancer, MET proto-oncogene, RET proto-oncogene, whole exome sequencing",
author = "Marialuisa Sponziello and Silvia Benvenuti and Alessandra Gentile and Valeria Pecce and Francesca Rosignolo and Virz{\`i}, {Anna Rita} and Melissa Milan and Comoglio, {Paolo M.} and Eric Londin and Paolo Fortina and Agnese Barnabei and Marialuisa Appetecchia and Ferdinando Marandino and Diego Russo and Sebastiano Filetti and Cosimo Durante and Antonella Verrienti",
year = "2018",
month = "3",
day = "1",
doi = "10.1002/humu.23378",
language = "English",
volume = "39",
pages = "371--377",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer

AU - Sponziello, Marialuisa

AU - Benvenuti, Silvia

AU - Gentile, Alessandra

AU - Pecce, Valeria

AU - Rosignolo, Francesca

AU - Virzì, Anna Rita

AU - Milan, Melissa

AU - Comoglio, Paolo M.

AU - Londin, Eric

AU - Fortina, Paolo

AU - Barnabei, Agnese

AU - Appetecchia, Marialuisa

AU - Marandino, Ferdinando

AU - Russo, Diego

AU - Filetti, Sebastiano

AU - Durante, Cosimo

AU - Verrienti, Antonella

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Whole exome sequencing (WES) was used to investigate two Italian siblings with wild-type RET genotype, who developed medullary thyroid cancers (MTCs) and, later, primary prostate and breast cancers, respectively. The proband's MTC harbored a p.Met918Thr RET mutation; his sister's MTC was RET/RAS wild-type. Both siblings had a germline mutation (p.Arg417Gln) in the extracellular Sema domain of the proto-oncogene MET. Experiments involving ectopic expression of MET p.Arg417Gln in MET-negative T47D breast cancer cells documented the mutant receptor's functionality and its ability to enhance cell migration and invasion. Our findings highlight a possible link between MET germline mutations and MTCs and suggest that MET p. Arg417Gln may promote an invasive malignant phenotype. The possibility that MTC can be driven/co-driven by a MET mutation has potential management implications, since the tyrosine-kinase inhibitor cabozantinib—approved for treating advanced MTCs—is a specific MET inhibitor.

AB - Whole exome sequencing (WES) was used to investigate two Italian siblings with wild-type RET genotype, who developed medullary thyroid cancers (MTCs) and, later, primary prostate and breast cancers, respectively. The proband's MTC harbored a p.Met918Thr RET mutation; his sister's MTC was RET/RAS wild-type. Both siblings had a germline mutation (p.Arg417Gln) in the extracellular Sema domain of the proto-oncogene MET. Experiments involving ectopic expression of MET p.Arg417Gln in MET-negative T47D breast cancer cells documented the mutant receptor's functionality and its ability to enhance cell migration and invasion. Our findings highlight a possible link between MET germline mutations and MTCs and suggest that MET p. Arg417Gln may promote an invasive malignant phenotype. The possibility that MTC can be driven/co-driven by a MET mutation has potential management implications, since the tyrosine-kinase inhibitor cabozantinib—approved for treating advanced MTCs—is a specific MET inhibitor.

KW - familial medullary thyroid cancer

KW - medullary thyroid cancer

KW - MET proto-oncogene

KW - RET proto-oncogene

KW - whole exome sequencing

UR - http://www.scopus.com/inward/record.url?scp=85041530089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041530089&partnerID=8YFLogxK

U2 - 10.1002/humu.23378

DO - 10.1002/humu.23378

M3 - Article

AN - SCOPUS:85041530089

VL - 39

SP - 371

EP - 377

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 3

ER -